Close Menu

Biodesix

NEW YORK (GenomeWeb News) – Biodesix said today that it has expanded a series E offering that raised $8.3 million in December.

NEW YORK (GenomeWeb News) – Biodesix today said that it has closed an $8.3 million Series E round of private financing.

Biodesix Raises $4M

NEW YORK (GenomeWeb News) – Molecular diagnostics company Biodesix said in a regulatory document that it has raised about $4 million in a private financing.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

NEW YORK (GenomeWeb News) – Biodesix has secured Medicare coverage for its VeriStrat lung cancer test, the company announced today.

Biodesix this week reported results from the first prospective clinical trial of its proteomic lung cancer test Veristrat.

In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.

Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said this week that they are collaborating on high-throughput iMALDI mass spec-based assays for determining genetic hemoglobin variants and diabetes risk.

Biodesix said this week it has entered a collaborative agreement with Bruker to support its VeriStrat diagnostic test, as well as future tests based on MALDI-TOF mass spectrometry.

NEW YORK (GenomeWeb News) – Biodesix said it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.